Tempus AI has EV/forward revenue under 10x, positive EBITDA, 33% genomics growth, and $150M in new contracts. Find out why ...

Between 2025 and 2030, the DNA-Modified Plant Extracts Market is forecast to nearly double, climbing from USD 950.7 million ...

Fintel reports that on December 15, 2025, Barclays maintained coverage of 10x Genomics (NasdaqGS:TXG) with a Overweight ...

Fintel reports that on December 11, 2025, Citigroup downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from Buy to ...

In a recent assessment by Citigroup analyst Patrick Donnelly, 10x Genomics, Inc. (TXG) has received a Neutral rating. The assessment reflects a price target set at $18, indicating a potential upside ...

During the quarter, we settled our worldwide patent litigation with Bruker on favorable terms and recognized an upfront ...

In a recent market development, Valero Energy Corporation (VLO) received a Neutral rating from Jean Ann Salisbury at BofA Securities, coupled with a price target increase reflecting an upside ...

Velo Protocol continues to build unstoppable momentum in Web3+ finance, stacking high impact partnerships that expand programmable payments, RWA tokenization, and borderless liquidity across Asia and ...

The IVD Quality Control industry presents opportunities driven by new technology and segments, resilient market fundamentals, and growth in biotechnology and genomics. Leveraging these trends can aid ...

Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure. Finding the right unprofitable companies is ...

In 2018, Chinese scientist He Jiankui shocked the world when he revealed that he had created the first gene-edited babies. Using Crispr, he tweaked the genes of three human embryos in an attempt to ...